Aclaris Therapeutics Inc 2025年季度报告

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule405 of RegulationS-T (§232.405 of this chapter) during the preceding 12months (or for such Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange The number of outstanding shares of the registrant’s common stock, par value $0.00001 per share, as of the close of businesson April 30, 2025 was108,281,239. INDEX TO FORM 10-Q PART I. FINANCIAL INFORMATION Item 1. Financial Statements2Unaudited Condensed Consolidated Balance Sheets as of March 31, 2025 andDecember 31, 20242Unaudited Condensed Consolidated Statements of Operations and ComprehensiveLoss for the three months ended March 31, 2025 and 20243Unaudited Condensed Consolidated Statements of Stockholders’ Equity for the threemonths ended March 31, 2025 and 20244Unaudited Condensed Consolidated Statements of Cash Flows for the three monthsended March 31, 2025 and 20245Notes to Unaudited Condensed Consolidated Financial Statements6Item 2. Management’s Discussion and Analysis of Financial Condition and Results ofOperations21Item 3. Quantitative and Qualitative Disclosures about Market Risk35Item 4. Controls and Procedures35PART II. OTHER INFORMATIONItem 1. Legal Proceedings36Item 1A. Risk Factors36Item 5. Other Information36Item 6. Exhibits37Signatures39 ACLARIS THERAPEUTICS, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND ACLARIS THERAPEUTICS, INC.CONDENSED CONSOLIDATED STATEMENTS OF The accompanying notes are an integral part of these condensed consolidated financial statements. ACLARIS THERAPEUTICS, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS ACLARIS THERAPEUTICS, INC.NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 1. Organization and Nature of Business Overview Aclaris Therapeutics, Inc. was incorporated under the laws of the State of Delaware in 2012.Aclaris Therapeutics, Inc. and its wholly owned subsidiaries are referred to collectively as the The Company is a clinical-stage biopharmaceutical company focused on developing novelsmall and large molecule product candidates for immuno-inflammatory diseases. The Company’s proprietary KINectdrug discovery platformcombined with its preclinical development capabilitiesallows the Company to identify and advance potential product candidates that it may developindependently or in collaboration with third parties.In addition to identifying and developing itsnovel product candidates, the Company is pursuing strategic alternatives, including identifying and Liquidity The Company’s condensed consolidated financial statements have been prepared on thebasis of continuity of operations, realization of assets and the satisfaction of liabilities in the ordinarycourse of business. As of March 31, 2025, the Company had cash, cash equivalents and marketablesecurities of $190.5million and an accumulated deficit of $917.9million. Since inception, theCompany has incurred net losses and negative cash flows from its operations. There can be noassurance that profitable operations will ever be achieved, and, if achieved, will be sustained on acontinuing basis. In addition, development activities, including clinical and preclinical testing of the Additional funds may not be available on a timely basis, on commercially acceptable terms,or at all, and such funds, if raised, may not be sufficient to enable the Company to continue toimplement its long-term business strategy. The Company's ability to raise additional capital may beadversely impacted by potentially worsening global economic conditions caused by a variety offactors including geopolitical tensions, inflationary pressures and tariff policies. If the Company isunable to raise sufficient additional capital or generate revenue from transactions with potential third- Inaccordance with Accounting Standards Codification(“ASC”)Subtopic 205-40,Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, the Companyevaluated whether there are conditions and events, considered in the aggregate, that raise substantialdoubt about the Company’s ability to continue as a going concern within one year after the date thatits condensed consolidated financial statements are issued.As of the report date, the Company does 2. Summary of Significant Accounting Policies Unaudited Interim Financial Information The accompanying condensed consolidated balance sheet as of March 31, 2025, thecondensed consolidated statements of operations and comprehen